CHOSOURCE™ expression platform

Drive efficiencies during development & production

The CHOSOURCE™ expression platform enables rapid identification of clones expressing high levels of recombinant therapeutic protein during development of a stable cell line.
Flexible licensing terms ensure this high-performance platform is easily accessible to meet the demands of cost-effective biomanufacturing.
Clear intellectual property position ensures freedom to operate in biotherapeutic production.


Why choose CHOSOURCE?

Industry standard with a proven track record

  • Easy-to-use CHO-K1 GS knockout cells have been widely adopted for bioproduction/manufacturing
  • More than 100 CHOSOURCE licenses sold worldwide since 2016 launch
  • 20 confirmed clinical laboratory regulatory submissions filed globally in the past 2 years
  • Ability to reach high expression levels – customers routinely report >4g/L with different molecules
  • Full history, traceability, IP clear and freedom-to-operate technology

Truly adaptable platform

  • Validated with different feeds, media, processes, molecules and vector technologies
  • Flexible, attractive pricing to meet your needs
  • Widely used Glutamine Synthetase (GS) selection is the gold standard for selection systems

Dedicated Horizon team

  • Accessible sales, licensing and scientific support teams to simplify purchase and setup
  • Extensive expertise using the platform to drive advancements in your pipeline


The CHOSOURCE expression platform consists of:

  • CHO-K1 GS knockout cell line (Cat #: HD-BIOP3)
    Well established, cGMP manufactured robust Glutamine Synthetase knockout CHO-K1 cell line produced using precision rAAV technology
  • Dual promoter expression vector
    Enables expression of an entire mAb from a single vector
  • Comprehensive protocols
  • Cell line history package to support regulatory submissions
    Fully documented traceable history of R&D and manufacture of the CHO-K1 GS KO cell line

Contact us to discuss your project

Required fields marked with * Required

Customize your CHO cell line to improve production
View engineering services


Learn more about CHOSOURCE

Download asset 


CHO-K1 GS KO Expression Platform

Streamline your manufacturing process and improve production to accelerate your biotherapeutic pipeline


Download asset


Discover how the CHOSOURCE CHO-K1 ADCC+ cell line increases Antibody Dependent Cellular Cytotoxicity (ADCC) making it a valuable tool in the production of biotherapeutics for Oncology, Anti-infectives and Auto-immune diseases.
Play video


Redesigning CHO: A new frontier in bioprocessing
See how Horizon is engineering improved CHO expression hosts for both research and commercial use to suit specific needs during discovery, development, and protein production.